3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Large Cell
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Pemetrexed
18
Carboplatin
16
Cisplatin
14
Paclitaxel
9
Gemcitabine
7
pembrolizumab
6
Crizotinib
5
osimertinib
4
amivantamab
4
Nivolumab
4
Docetaxel
4
lazertinib
3
Vinorelbine
3
Ipilimumab
3
Afatinib
3
selpercatinib
2
lorlatinib
2
durvalumab
2
cemiplimab
2
atezolizumab
2
alectinib
2
Gefitinib
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zenocutuzumab
1
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
telisotuzumab vedotin
1
taletrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma, Non-Small-Cell Lung
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA